ABBV / AbbVie Inc
as of 2026-03-15
Bias: MixedRisk: NormalMixed structure, RSI neutral, risk normal
Last
232.35
1D -1.63% • 5D +3.41% • 1M +2.96%
Updating…
Job #5086 • queued • 0/0 requests
Company
Abbvie Inc is a biopharmaceutical company that emerged from Abbott Laboratories in 2013. The company specializes in developing treatments for a range of serious health conditions, including immunology, oncology, and neuroscience. Abbvie's flagship product, Humira, has been a significant driver of its revenue, although the company is actively expanding its pipeline with new therapies. Abbvie is committed to research and development, aiming to address unmet medical needs and improve patient outcomes globally.
Mini chart (last 120 D1 closes)
2025-10-10 → 2026-03-05
1D
-1.63%
5D
+3.41%
1M
+2.96%
Vol (20d)
24.0%
Weather meter
Δ +0
Overall62
Trend60
Volatility70
Sentiment50
Technicals
MA20
227.85
Above short-term trend
MA50
224.39
Above medium-term trend
MA200
—
RSI14
56.1
Neutral
What traders watch now
Support (MA50)
224.39
Resistance (MA200)
—
Key risk
Range / chop
Time horizon
2–10 trading days